PT - JOURNAL ARTICLE AU - Nita H. Shah AU - Ankush H. Suthar AU - Ekta N. Jayswal AU - Nehal Shukla AU - Jagdish Shukla TI - Modelling the impact of Plasma Therapy and Immunotherapy for Recovery of COVID-19 Infected Individuals AID - 10.1101/2020.05.23.20110973 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.23.20110973 4099 - http://medrxiv.org/content/early/2020/05/24/2020.05.23.20110973.short 4100 - http://medrxiv.org/content/early/2020/05/24/2020.05.23.20110973.full AB - Since the first case of COVID-19 was detected in Wuhan, China in December 2019, COVID-19 has become a pandemic causing a global economic and public health emergency. There is no known treatment or vaccine available for COVID-19 to date. Immunotherapy and plasma therapy has been used with satisfactory efficacy over the past two decades in many viral infections like SARS (Systemic Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), and H1N1. Limited data from China show clinical benefit, radiological resolution, reduction in viral loads, and improved survival. Our aim is to create a mathematical model for COVID-19 transmission and then apply various control parameters to see their effects on recovery from COVID-19 disease. We have formulated a system of non-linear ordinary differential equations, calculated basic reproduction R0, and applied five different controls (self-isolation, quarantine, herd immunity, immunotherapy, plasma therapy) to test the effectiveness of control strategy. Control optimality was checked by Lagrangian functions. Numerical simulations and bifurcation analyses were carried out. The study concludes that the COVID-19 outbreak can be controlled up to a significant level three weeks after applying all the control strategies together. These strategies lead to a reduction in hospitalization and a rise in recovery from infection. Immunotherapy is highly effective initially in hospitalized infected individuals however better results were seen in the long term with plasma therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe second author (AHS) is funded by a Junior Research Fellowship from the Council of Scientific & Industrial Research (file no.-09/070(0061)/2019-EMR-I). The third author (ENJ) is funded by UGC granted National Fellowship for Other Backward Classes (NFO-2018-19-OBC-GUJ-71790).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is not a clinical trial. No human subjects involved. IRB approval not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data derived from our mathematical calculations in the paper that are available to all the readers.